Literature DB >> 29736852

Thoracic involvement in Erdheim-Chester disease: computed tomography imaging findings and their association with the BRAFV600E mutation.

S Mojdeh Mirmomen1, Arlene Sirajuddin2, Moozhan Nikpanah1, Rolf Symons1, Anna K Paschall1, Ioannis Papageorgiou3, William A Gahl4, Kevin O'Brien4, Juvianee I Estrada-Veras4, Ashkan A Malayeri5.   

Abstract

OBJECTIVES: To investigate the computed tomography (CT) thoracic findings in Erdheim-Chester disease (ECD) and evaluate the association of these findings with the BRAFV600E mutation.
METHODS: This was a prospective study of patients with ECD (n=61, men=46) who underwent thoracic CT imaging. CT examinations were independently interpreted by two experienced radiologists. Association of imaging findings with BRAFV600E was achieved via the Chi-square or Fisher's exact test and odds ratios (OR) with 95% confidence intervals (CI), as appropriate.
RESULTS: Fifty-five ECD patients (90%) showed pulmonary findings, which included interlobular septal thickening (69%), pulmonary nodules (62%), airway thickening (13%) and ground glass opacities (36%). Pulmonary nodules were classified by the pattern of distribution: subpleural regions (36%), lung parenchyma (13%) and both regions (13%). Pleural and mediastinal involvement were present in 15% and 62% of cases, respectively. The most common mediastinal finding was sheathing of the right coronary artery (34%), followed by sheathing of the thoracic aorta (30%). The BRAFV600E mutation, positive in 31 patients, was associated with the frequency of sheathing of the coronary arteries (p = 0.01).
CONCLUSIONS: Of the thoracic findings reported in this study, we found a statistically significant positive association between the BRAFV600E mutation and presence of coronary artery sheathing. KEY POINTS: • To assess the degree of thoracic involvement in ECD with CT. • BRAF V600E mutation has a high association with right coronary artery sheathing. • BRAF V600E genetic testing detects patients at high risk of developing RCA sheathing.

Entities:  

Keywords:  Erdheim-Chester disease; Genetic association study; Multidetector computed tomography; Proto-oncogene proteins B-raf; Thorax

Mesh:

Substances:

Year:  2018        PMID: 29736852     DOI: 10.1007/s00330-018-5421-3

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  23 in total

Review 1.  Erdheim-Chester disease.

Authors:  Julien Haroche; Laurent Arnaud; Zahir Amoura
Journal:  Curr Opin Rheumatol       Date:  2012-01       Impact factor: 5.006

2.  Erdheim-Chester disease: CT findings of thoracic involvement.

Authors:  Anne-Laure Brun; Diane Touitou-Gottenberg; Julien Haroche; Dan Toledano; Philippe Cluzel; Catherine Beigelman-Aubry; Jean-Charles Piette; Zahir Amoura; Philippe A Grenier
Journal:  Eur Radiol       Date:  2010-06-20       Impact factor: 5.315

3.  Imaging of thoracoabdominal involvement in Erdheim-Chester disease.

Authors:  Elisabeth Dion; Claire Graef; Julien Haroche; Raphaële Renard-Penna; Philippe Cluzel; Bertrand Wechsler; Jean-Charles Piette; Philippe A Grenier
Journal:  AJR Am J Roentgenol       Date:  2004-11       Impact factor: 3.959

Review 4.  Erdheim-Chester Disease: a comprehensive review of the literature.

Authors:  Roei D Mazor; Mirra Manevich-Mazor; Yehuda Shoenfeld
Journal:  Orphanet J Rare Dis       Date:  2013-09-08       Impact factor: 4.123

5.  Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease.

Authors:  Fleur Cohen Aubart; Jean-François Emile; Philippe Maksud; Damien Galanaud; Philippe Cluzel; Neila Benameur; Olivier Aumaitre; Zahir Amoura; Julien Haroche
Journal:  Br J Haematol       Date:  2016-10-06       Impact factor: 6.998

6.  Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease.

Authors:  Eli L Diamond; Lorenzo Dagna; David M Hyman; Giulio Cavalli; Filip Janku; Juvianee Estrada-Veras; Marina Ferrarini; Omar Abdel-Wahab; Mark L Heaney; Paul J Scheel; Nancy K Feeley; Elisabetta Ferrero; Kenneth L McClain; Augusto Vaglio; Thomas Colby; Laurent Arnaud; Julien Haroche
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

Review 7.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

Review 8.  Erdheim-Chester disease.

Authors:  Corrado Campochiaro; Alessandro Tomelleri; Giulio Cavalli; Alvise Berti; Lorenzo Dagna
Journal:  Eur J Intern Med       Date:  2015-04-10       Impact factor: 4.487

9.  Pulmonary involvement with Erdheim-Chester disease: radiographic and CT findings.

Authors:  K H Wittenberg; S J Swensen; J L Myers
Journal:  AJR Am J Roentgenol       Date:  2000-05       Impact factor: 3.959

Review 10.  Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review.

Authors:  Julien Haroche; Zahir Amoura; Elisabeth Dion; Bertrand Wechsler; Nathalie Costedoat-Chalumeau; Patrice Cacoub; Richard Isnard; Thierry Généreau; Janine Wechsler; Nina Weber; Claire Graef; Philippe Cluzel; Philippe Grenier; Jean-Charles Piette
Journal:  Medicine (Baltimore)       Date:  2004-11       Impact factor: 1.889

View more
  2 in total

Review 1.  Cardiothoracic manifestations of Erdheim-Chester disease.

Authors:  Jeeban Paul Das; Lola Xie; Chris C Riedl; Sara A Hayes; Michelle S Ginsberg; Darragh F Halpenny
Journal:  Br J Radiol       Date:  2019-08-14       Impact factor: 3.039

2.  Clinical and Histopathologic Features of Interstitial Lung Disease in Erdheim⁻Chester Disease.

Authors:  Sara G Haroutunian; Kevin J O'Brien; Juvianee I Estrada-Veras; Jianhua Yao; Louisa C Boyd; Kavya Mathur; William A Gahl; S Mojdeh Mirmomen; Ashkan A Malayeri; David E Kleiner; Elaine S Jaffe; Bernadette R Gochuico
Journal:  J Clin Med       Date:  2018-08-28       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.